This inventor holds 1 USPTO granted patent and 1 published patent application, plus 1 CIPO patent and 2 EPO patents. Top assignee: Leland Stanford Junior University. Active years: 2016.
Company Filing History:
Years Active: 2016
Title: David Solow-Cordero: Innovator in Pulmonary Arterial Hypertension Treatment
Introduction
David Solow-Cordero is an accomplished inventor based in Stanford, California. He has made significant contributions to the field of medicine, particularly in the treatment of pulmonary arterial hypertension. His innovative approach has the potential to improve the lives of many individuals suffering from this condition.
Latest Patents
David Solow-Cordero holds a patent for the use of FK506 for the treatment of pulmonary arterial hypertension. This patent describes a method of reducing pulmonary arterial hypertension in a mammal by administering FK506. The method is particularly effective for mammals with pulmonary arterial hypertension associated with defective MBPR2 signaling. The dosage is designed to be sufficient to reduce blood pressure in the pulmonary artery of the mammal.
Career Highlights
David is affiliated with Leland Stanford Junior University, where he conducts research and develops innovative treatments. His work has garnered attention for its potential impact on the medical community and patient care.
Collaborations
David has collaborated with notable colleagues, including Edda Spiekerkoetter and Marlene Rabinovitch. These partnerships have enhanced his research efforts and contributed to advancements in the field.
Conclusion
David Solow-Cordero's work in the treatment of pulmonary arterial hypertension exemplifies the importance of innovation in medicine. His contributions are paving the way for new therapeutic approaches that could significantly benefit patients.